aspartic acid has been researched along with Pancreatic Neoplasms in 26 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Overall safety of PCI-27483-gemcitabine (n = 26) was similar to gemcitabine alone (n = 16), with a higher incidence of mostly low-grade bleeding events (65% vs." | 5.30 | A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. ( Cole, G; Gabrail, NY; James, D; Khorana, AA; Ramanathan, RK; Shah, S; Thomas, GW; Wong, S; Zhou, C, 2019) |
| "To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma." | 3.69 | Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "Inhibiting pancreatic cancer progression after chemotherapy is a rational application of this metabolism-disturbing combination strategy." | 1.48 | Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. ( Chen, C; Fei, K; Guo, L; Ju, R; Li, J; Li, S; Ye, C; Zhang, D; Zhu, L, 2018) |
| "Six CDKN2A families had pancreatic cancer." | 1.31 | Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Bermudez, J | 1 |
| Badgley, MA | 1 |
| Prasad, S | 1 |
| Baudrier, L | 1 |
| Liu, Y | 1 |
| La, K | 1 |
| Soula, M | 1 |
| Williams, RT | 1 |
| Yamaguchi, N | 1 |
| Hwang, RF | 1 |
| Taylor, LJ | 1 |
| de Stanchina, E | 1 |
| Rostandy, B | 1 |
| Alwaseem, H | 1 |
| Molina, H | 1 |
| Bar-Sagi, D | 1 |
| Birsoy, K | 1 |
| Abrego, J | 2 |
| Sanford-Crane, H | 1 |
| Oon, C | 1 |
| Xiao, X | 1 |
| Betts, CB | 1 |
| Sun, D | 1 |
| Nagarajan, S | 1 |
| Diaz, L | 1 |
| Sandborg, H | 1 |
| Bhattacharyya, S | 1 |
| Xia, Z | 1 |
| Coussens, LM | 1 |
| Tontonoz, P | 1 |
| Sherman, MH | 1 |
| Gebregiworgis, T | 1 |
| Purohit, V | 1 |
| Shukla, SK | 1 |
| Tadros, S | 1 |
| Chaika, NV | 1 |
| Mulder, SE | 1 |
| Gunda, V | 1 |
| Singh, PK | 1 |
| Powers, R | 1 |
| Ju, R | 1 |
| Fei, K | 1 |
| Li, S | 1 |
| Chen, C | 1 |
| Zhu, L | 1 |
| Li, J | 1 |
| Zhang, D | 1 |
| Guo, L | 1 |
| Ye, C | 1 |
| Ramanathan, RK | 1 |
| Thomas, GW | 1 |
| Khorana, AA | 1 |
| Shah, S | 1 |
| Zhou, C | 1 |
| Wong, S | 1 |
| Cole, G | 1 |
| James, D | 1 |
| Gabrail, NY | 1 |
| Elliott, IA | 1 |
| Dann, AM | 1 |
| Xu, S | 1 |
| Kim, SS | 1 |
| Abt, ER | 1 |
| Kim, W | 1 |
| Poddar, S | 1 |
| Moore, A | 1 |
| Zhou, L | 2 |
| Williams, JL | 1 |
| Capri, JR | 1 |
| Ghukasyan, R | 1 |
| Matsumura, C | 1 |
| Tucker, DA | 1 |
| Armstrong, WR | 1 |
| Cabebe, AE | 1 |
| Wu, N | 1 |
| Li, L | 1 |
| Le, TM | 1 |
| Radu, CG | 1 |
| Donahue, TR | 1 |
| Yang, H | 1 |
| Shi, Q | 1 |
| Zhao, Y | 1 |
| Lin, H | 1 |
| Zhang, M | 1 |
| Zhao, S | 1 |
| Yang, Y | 1 |
| Ling, ZQ | 1 |
| Guan, KL | 1 |
| Xiong, Y | 1 |
| Ye, D | 1 |
| Wang, HQ | 1 |
| Meng, X | 1 |
| Gao, YY | 1 |
| Liu, BQ | 1 |
| Niu, XF | 1 |
| Zhang, HY | 1 |
| Du, ZX | 1 |
| Ray, KC | 1 |
| Bell, KM | 1 |
| Yan, J | 1 |
| Gu, G | 1 |
| Chung, CH | 1 |
| Washington, MK | 1 |
| Means, AL | 1 |
| Rachagani, S | 1 |
| Senapati, S | 1 |
| Chakraborty, S | 1 |
| Ponnusamy, MP | 1 |
| Kumar, S | 1 |
| Smith, LM | 1 |
| Jain, M | 1 |
| Batra, SK | 1 |
| Yao, X | 1 |
| Zeng, M | 1 |
| Wang, H | 1 |
| Fei, S | 1 |
| Rao, S | 1 |
| Ji, Y | 1 |
| Pettersson, F | 1 |
| Dalgleish, AG | 1 |
| Bissonnette, RP | 1 |
| Colston, KW | 1 |
| Whitehead, RP | 1 |
| Benedetti, JK | 1 |
| Abbruzzese, JL | 2 |
| Ardalan, B | 3 |
| Goodwin, JW | 1 |
| Balcerzak, SP | 1 |
| Samlowski, WE | 1 |
| Lenz, HJ | 1 |
| Macdonald, JS | 2 |
| Jiao, L | 1 |
| Hassan, MM | 1 |
| Bondy, ML | 1 |
| Evans, DB | 1 |
| Li, D | 1 |
| Ollila, S | 1 |
| Dermadi Bebek, D | 1 |
| Greenblatt, M | 1 |
| Nyström, M | 1 |
| Erlichman, C | 1 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Redei, I | 1 |
| Green, F | 1 |
| Hoffman, JP | 1 |
| Weiner, LM | 1 |
| Scher, R | 1 |
| O'Dwyer, PJ | 2 |
| Ucar, A | 1 |
| Reddy, R | 1 |
| Livingstone, AS | 1 |
| Markoe, A | 1 |
| Schwade, J | 1 |
| Richman, SP | 2 |
| Donofrio, K | 1 |
| Finkelstein, SD | 1 |
| Przygodzki, R | 1 |
| Pricolo, VE | 1 |
| Sayegh, R | 1 |
| Bakker, A | 1 |
| Swalsky, PA | 1 |
| Keller, G | 1 |
| Harstrick, A | 1 |
| Köhne, CH | 1 |
| Hiddemann, W | 1 |
| Preusser, P | 1 |
| Strumberg, D | 1 |
| Berns, T | 1 |
| Seeber, S | 1 |
| Wilke, H | 1 |
| Schmoll, HJ | 1 |
| Goldstein, AM | 1 |
| Struewing, JP | 1 |
| Chidambaram, A | 1 |
| Fraser, MC | 1 |
| Tucker, MA | 1 |
| Rosvold, E | 1 |
| Schilder, R | 1 |
| Walczak, J | 1 |
| DiFino, SM | 1 |
| Flynn, PJ | 1 |
| Banerjee, TK | 1 |
| Heim, WJ | 1 |
| Engstrom, PF | 1 |
| Ozols, RF | 1 |
| Morrell, LM | 1 |
| Bach, A | 1 |
| Goodman, P | 1 |
| Fleming, TR | 1 |
| Nagata, Y | 1 |
| Abe, M | 1 |
| Motoshima, K | 1 |
| Nakayama, E | 1 |
| Shiku, H | 1 |
| Singh, G | 1 |
| Silberman, H | 1 |
7 trials available for aspartic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 2019 |
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res | 2004 |
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 1994 |
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali | 1994 |
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1992 |
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 1991 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
19 other studies available for aspartic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia.
Topics: Aspartic Acid; Cell Line, Tumor; Humans; Hypoxia; Pancreatic Neoplasms; Proto-Oncogene Proteins p21( | 2022 |
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Topics: Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Pancreatic Ductal; Fatty Acids; Humans; Ligan | 2022 |
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Topics: Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Pancreatic Ductal; Fatty Acids; Humans; Ligan | 2022 |
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Topics: Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Pancreatic Ductal; Fatty Acids; Humans; Ligan | 2022 |
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Topics: Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Pancreatic Ductal; Fatty Acids; Humans; Ligan | 2022 |
Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells.
Topics: Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; DNA Replication; Glucose; Gl | 2017 |
Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Cell Respiratio | 2018 |
Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion.
Topics: Animals; Aspartic Acid; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chloroquine; Female; Humans; | 2019 |
SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth.
Topics: Acetylation; Animals; Aspartate Aminotransferase, Mitochondrial; Aspartic Acid; Biological Transport | 2015 |
Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Caspa | 2010 |
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.
Topics: Amino Acid Substitution; Animals; Aspartic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Ce | 2011 |
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Aspartic Acid; Cadherins; Down-Regulation; Gene Ex | 2011 |
Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results.
Topics: Adult; Aged; Aspartic Acid; Biomarkers, Tumor; Choline; Dipeptides; Fatty Acids, Unsaturated; Female | 2012 |
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax.
Topics: Adenocarcinoma; Alitretinoin; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Aspartic Acid; bc | 2002 |
The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.
Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Asparagine; Aspartic Acid; Carcinoma, Pancreatic Duct | 2007 |
Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification.
Topics: Asparagine; Aspartic Acid; Biliary Tract Neoplasms; Blotting, Western; Colorectal Neoplasms, Heredit | 2008 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
K-ras-2 topographic genotyping of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Alanine; Arginine; Aspartic Acid; Codon; Cysteine; DNA, Neoplasm; Exons; Forecasting | 1994 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 1997 |
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G | 2000 |
Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese.
Topics: Adult; Aged; Asian People; Aspartic Acid; Codon; Female; Genes, ras; Glycine; Humans; Japan; Male; M | 1990 |